Journal
TUBERCULOSIS
Volume 140, Issue -, Pages -Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.tube.2023.102342
Keywords
Spectinamide 1599; Mycobacterium; Tuberculosis; Phenotypically tolerant isoform; Hollow fiber infection model
Categories
Ask authors/readers for more resources
Spectinamides are a novel series of spectinomycin analogs being developed for the treatment of tuberculosis. Spectinamide 1599, the preclinical lead, shows strong efficacy against tuberculosis with good pharmacokinetic properties and excellent safety profiles. It is more effective against log phase bacteria compared to other resistant forms, similar to the established antituberculosis drug isoniazid.
Spectinamides are a novel series of spectinomycin analogs being developed for the treatment of tuberculosis. The preclinical lead spectinamide 1599 is an antituberculosis drug that possesses robust in vivo efficacy, good pharmacokinetic properties, and excellent safety profiles in rodents. In individuals infected with Mycobacterium tuberculosis or Mycobacterium bovis, causative agents of tuberculosis, the host immune system is capable of restraining these mycobacteria within granulomatous lesions. The harsh microenvironmental conditions of these granuloma lead to phenotypic transformation of mycobacteria. Phenotypically transformed bacteria display suboptimal growth, or complete growth arrest and are frequently associated with drug tolerance. Here we quantified the effect of spectinamide 1599 on log-phase and phenotypically tolerant isoforms of Mycobacterium bovis BCG using various in vitro approaches as a first indicator of spectinamide 1599 activity against various mycobacterial isoforms. We also used the hollow fiber infection model to establish time-kill curves and deployed pharmacokinetic/pharmacodynamic modeling to characterize the activity differences of spectinamide 1599 towards the different phenotypic subpopulations. Our results indicate that spectinamide 1599 is more efficacious against log phase bacteria when compared to its activity against other phenotypically tolerant forms such as acid phase bacteria and hypoxic phase bacteria, a behavior similar to the established antituberculosis drug isoniazid.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available